Skip to main navigation

Investor Relations

January 05, 2021

Abivax publishes review in Drug Discovery Today on mechanism of action and transformative potential of ABX464 as therapy for inflammatory diseases

December 22, 2020

Abivax’s Covid-19 phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government’s clinical trial council

December 21, 2020

Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of major clinical milestones

December 09, 2020

Abivax establishes clinical, regulatory and manufacturing framework for ABX464 phase 3 program and potential commercialization in 2021

December 03, 2020

Abivax 2021 Financial Communication Calendar